{
    "2018-08-20": [
        [
            {
                "time": "",
                "original_text": "沃森生物：吸附无细胞百白破联合疫苗年产能超1000万剂",
                "features": {
                    "keywords": [
                        "沃森生物",
                        "吸附无细胞百白破联合疫苗",
                        "年产能",
                        "1000万剂"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "[推荐评级] 沃森生物(300142)半年报点评：上半年业绩扭亏 静待PCV13上市带动业绩爆发",
                "features": {
                    "keywords": [
                        "沃森生物",
                        "半年报",
                        "扭亏",
                        "PCV13",
                        "业绩爆发"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "[增持评级] 深度*公司*沃森生物(300142)中报点评：2018H1扭亏为盈 静待PCV13获批",
                "features": {
                    "keywords": [
                        "沃森生物",
                        "中报",
                        "扭亏为盈",
                        "PCV13",
                        "获批"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}